Research & Publications
![application/pdf](/++resource++zms_/img/mime_type.application_pdf.gif)
Molecular Biology: Measuring and Reporting BCR-ABL Transcripts Level
Giuseppe Saglio
Giuseppe Saglio
![application/pdf](/++resource++zms_/img/mime_type.application_pdf.gif)
Relative Risk (Sokal & Hasford): Relationship with Treatment Results
Michele Baccarani
Michele Baccarani
![application/pdf](/++resource++zms_/img/mime_type.application_pdf.gif)
Imatinib in the Early Chronic Phase
Richard Larson
Richard Larson
Diagnostic and Pre-treatment Work-up
François Guilhot
François Guilhot
![application/pdf](/++resource++zms_/img/mime_type.application_pdf.gif)
Long-term benefit of imatinib for patients newly diagnosed with CML in chronic phase: The 5-year update from IRIS study
Brian J. Druker
Brian J. Druker
![application/pdf](/++resource++zms_/img/mime_type.application_pdf.gif)
Response-related Prognostic Factors: The Cytogenetic Response
Michael Deininger
Michael Deininger
![application/pdf](/++resource++zms_/img/mime_type.application_pdf.gif)
Response-related Prognostic Factors: The Molecular Response
Giuseppe Saglio
Giuseppe Saglio
![application/pdf](/++resource++zms_/img/mime_type.application_pdf.gif)
Bcr-Abl Kinase Domain Mutations
Martin Müller
Martin Müller
Response Definition, Evaluation and Monitoring
Michele Baccarani
Michele Baccarani
![application/pdf](/++resource++zms_/img/mime_type.application_pdf.gif)
Treatment Policy
Rüdiger Hehlmann
Rüdiger Hehlmann
Venice Meeting Highlights: Key lessons
Michele Baccarani, Rüdiger Hehlmann
Michele Baccarani, Rüdiger Hehlmann